Purpose: To describe intracameral toxic effects of cefuroxime at a higher dose than recommended in cataract surgery.
Methods: Retrospective study of 8 eyes of 8 patients who inadvertently received 12.5 mg/0.1 ml of intracameral cefuroxime due to a dilution error, at the end of the cataract surgery. All patients underwent a strict ophthalmology follow-up for 6 months.
Results: All patients presented with a marked anterior segment inflammation with corneal oedema that resolved completely in all cases (between 5 days and 3 months). At 6 months of follow-up a statistically significant difference was found in the corneal endothelial cell density when compared with the fellow eye (P = .038), being <1000 cells/mm in 3 cases. Three patients (37.5%) showed early macular oedema, with subfoveal ellipsoid layer disruption in one case as a permanent sequel. One patient developed an optic neuropathy with associated afferent pupillary defect.
Conclusions: Although 1 mg/0.1 ml of intracameral cefuroxime has been shown to reduce the incidence of endophthalmitis, its overdose can have potentially toxic eye effects in both anterior and posterior segments.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.oftale.2020.12.011 | DOI Listing |
Int Ophthalmol
January 2025
Cleveland Clinic Abu Dhabi, Eye Institute, Abu Dhabi, United Arab Emirates.
Purpose: To describe the safety and assess the feasibility of using intracameral cefuroxime sodium (Aprokam®) during congenital cataract surgery as a preventive measure for endophthalmitis.
Design: Monocentric, prospective, observational pilot study.
Setting: San Giuseppe Hospital, University of Milan, Milan, Italy.
J Fr Ophtalmol
December 2024
Quinze-Vingts National Ophthalmology Hospital, IHU FOReSIGHT, 28, rue de Charenton, 75012 Paris, France; Sorbonne Université, Inserm, CNRS, Institut de la Vision, IHU FOReSIGHT, 17, rue Moreau, 75012 Paris, France.
Purpose: Acute postoperative endophthalmitis (APE) is a rare but severe complication of cataract surgery. During the most recent decades, the use of povidone-iodine (PVI) before surgery combined with intracameral cefuroxime has drastically reduced the incidence of endophthalmitis. The goal of this study is to describe the changes in endophthalmitis rates after cataract surgery over the past two decades in a large tertiary ophthalmology center.
View Article and Find Full Text PDFArch Soc Esp Oftalmol (Engl Ed)
December 2024
Departamento de Investigación y Desarrollo, Clínica Baviera, Valencia, Spain.
Purpose: To analyze the incidence, causes, risk factors and treatment of acute postoperative endophthalmitis (POE) after phacoemulsification in a private ophthalmological group.
Design: Uncontrolled retrospective observational study of all cases of POE over 22 years.
Material And Methods: 369,476 eyes were included after phacoemulsification in 41 surgical centers of the Clínica Baviera-AIER EYE Group from 2002 to 2023.
Arq Bras Oftalmol
November 2024
Ophthalmology Department, Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, SP, Brazil.
J Cataract Refract Surg
August 2024
From the Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Friling, Montan); Capio Medocular, Specialistläkarhuset, Sundsvall, Sweden (Friling); Department of Ophthalmology, Umeå University Hospital, Umeå, Sweden (Friling); Memira Eye Center, Jönköping, Sweden (Bro); Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden (Bro); Department of Clinical Sciences, Ophthalmology, Faculty of Medicine, Lund University, Lund, Sweden (Lundström); Department of Anterior Segment Surgery, St Erik Eye Hospital, Stockholm, Sweden (Montan).
Purpose: To study the incidence, predictive factors, etiology, and visual consequences of postoperative endophthalmitis (PE) in relation to 3 intracameral (IC) antibiotic regimes.
Setting: Swedish National Cataract Register entries from 2011 through 2017.
Design: Observational retrospective study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!